Yiviva, a clinical-stage biotechnology company pioneering systems biology-driven therapeutics, announced data from its ...

Thirty years on, miRNA-based diagnostic and therapeutic agents for HCC remain a work-in-progress (WIP) and no current miRNA HCC clinical trial has progressed to phase 4. The question remains why ...

In this study, a Tp53 -deficient HCC mouse model was used to evaluate the effects of CDC7i-induced cancer cell senescence on the liver TME. Two time points were selected for in-depth TME analyses, ...

Liver transplantation remains the only curative treatment for patients with hepatocellular carcinoma (HCC), but the development of other therapies should spark a rethinking of how and when ...

In their research article summary, the authors noted, “Using spontaneous preclinical models of HCC with distinct immunotypes, we show that the EPO/EPOR axis functions as an immunosuppressive ...

It's officially NFL Draft week! 32 teams will be making their selections this week in hopes of building their roster into a championship squad. That means now i ...

Abstract. Hepatocellular carcinoma (HCC) is the most common type of liver cancer. Its incidence is increasing and is closely related to advanced liver disease. Interactions in the HCC microenvironment ...

NFU Cymru head of policy Dylan Morgan told the committee HCC also needed to “look at wider communication channels to get its message across”. “Producers in Wales pay a significant amount of ...

Pilatus Biosciences Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its leading molecule, PLT012, for treating liver and intrahepatic ...

T-cell receptor repertoire analysis in the context of transarterial chemoembolization synergy with systemic therapy for hepatocellular carcinoma Peer-Reviewed Publication Xia & He Publishing Inc.

Background The determinants of the response to checkpoint immunotherapy in hepatocellular carcinoma (HCC) remain poorly understood. The organisation of the immune response in the tumour ...

The complex dynamics between liver cancer stem cells (CSCs) and immune cells within the tumor microenvironment (TME) are central to the progression of liver cancer. These interactions are critical ...